Rohan Palekar, 89bio CEO
December 7, 2023 07:04 AM ESTUpdated 07:15 AM
Financing
R&D

Up­dat­ed: 89bio prices $150M pub­lic of­fer­ing for PhI­II de­vel­op­ment of NASH drug

Katherine Lewin

News Reporter

89bio an­nounced an up­sized $150 mil­lion pub­lic of­fer­ing of its com­mon stock on Thurs­day, just a few days af­ter the com­pa­ny …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

BioN­Tech set­tles with NIH, UPenn in Covid vac­cine dis­putes and will pay roy­al­ties

FDA ap­proves sub­cu­ta­neous ver­sion of Bris­tol My­er­s' Op­di­vo

J&J part­ners on STAT6; As­traZeneca, Dai­ichi with­draw lung can­cer drug EMA app

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

A service from the Financial Times